Qualitative and quantitative intratumoral changes in gene expression following cyclophosphamide injection and the adoptive transfer of T cells: the potential contribution of tumor-associated macrophages.
Adoptive immunotherapy (AIT) of mice bearing the MCA/76-9 rhabdomyosarcoma in combination with cyclophosphamide (CY) injection results in the permanent regression of tumors. This report is concerned with changes in the tumor-associated macrophage (TAM) population and the influence of both CY injection and CY/AIT on their potential functions. Sequential analyses of FcR, MAC-I and Class-II MHC antigen expressed by tumor-associated cells (TAC) showed that CY injection or CY/AIT induced marked increases in the proportions of all 3 parameters as compared with the relatively stable levels in progressing tumors. These changes were time- and treatment-related. The mean MAC-I fluorescence (antigen density per cell) increased nearly 2-fold by 48 hr after CY injection, regardless of subsequent AIT. In contrast, the density of Class-II antigen per cell declined by as much as 75% within 48 hr after CY injection and did not recover by 7 days. This initial decline was also seen after CY/AIT and was followed by a rapid recovery to near-normal values by day 7. Northern analysis of RNA isolated from whole tumor tissue indicated wide fluctuations in expression of the typical macrophage genes encoding the proteins MAC-I, IL-I alpha, IL-I beta, TNF alpha, IA beta and c-fms. However, with the exception of MAC-I and IL-1 alpha/IL-1 beta mRNA, the modifications appeared to be qualitative rather than representing changes in the proportions of TAM. The data suggest that the changes in membrane antigen and gene expression by TAM reflect a complex interaction between TAM and their environment, in particular tumor cells and tumor-infiltrating lymphocytes. In addition, it is evident that CY injection per se is responsible for defined fundamental changes that presumably influence the outcome of AIT.
Evans
R
R
Jackson Laboratory, Bar Harbor, ME 04609.
Kamdar
S J
SJ
Duffy
T M
TM
D000818:Animals; D015152:Blotting, Northern; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005434:Flow Cytometry; D015870:Gene Expression; D016219:Immunotherapy, Adoptive; D007375:Interleukin-1 / Q000235:genetics; D016177:Macrophage-1 Antigen / Q000032:analysis / Q000235:genetics; D008264:Macrophages / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D012333:RNA, Messenger / Q000378:metabolism; D011961:Receptors, Fc / Q000032:analysis; D012208:Rhabdomyosarcoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D007375:Interleukin-1; D016177:Macrophage-1 Antigen; D012333:RNA, Messenger; D011961:Receptors, Fc; D014409:Tumor Necrosis Factor-alpha; D003520:Cyclophosphamide